{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:31:13Z","timestamp":1792704673430,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1124\/jpet.109.152520","type":"journal-article","created":{"date-parts":[[2009,6,4]],"date-time":"2009-06-04T02:04:33Z","timestamp":1244081073000},"page":"939-947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Targeting Prostaglandin E2 EP1 Receptors Prevents Seizure-Associated P-glycoprotein Up-Regulation"],"prefix":"10.1016","volume":"330","author":[{"given":"Anton","family":"Pekcec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Unkr\u00fcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli","family":"Schlichtiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna","family":"Soerensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika M.S.","family":"Hartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin A.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Gorter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Potschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.152520_bib1","doi-asserted-by":"crossref","unstructured":"Ahmad AS, Ahmad M, de Brum-Fernandes AJ, and Dor\u00e9 S (2005) Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 1066: 71-77.","DOI":"10.1016\/j.brainres.2005.10.068"},{"key":"10.1124\/jpet.109.152520_bib2","doi-asserted-by":"crossref","unstructured":"Baik EJ, Kim EJ, Lee SH, and Moon C (1999) Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 843: 118-129.","DOI":"10.1016\/S0006-8993(99)01797-7"},{"key":"10.1124\/jpet.109.152520_bib3","doi-asserted-by":"crossref","unstructured":"Balboa MA, Varela-Nieto I, Killermann Lucas K, and Dennis EA (2002) Expression and function of phospholipase A(2) in brain. FEBS Lett 531: 12-17.","DOI":"10.1016\/S0014-5793(02)03481-6"},{"key":"10.1124\/jpet.109.152520_bib4","doi-asserted-by":"crossref","unstructured":"Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, and Potschka H (2008) Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 73: 1444-1453.","DOI":"10.1124\/mol.107.041210"},{"key":"10.1124\/jpet.109.152520_bib5","doi-asserted-by":"crossref","unstructured":"Bilak M, Wu L, Wang Q, Haughey N, Conant K, St Hillaire C, and Andreasson K (2004) PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol 56: 240-248.","DOI":"10.1002\/ana.20179"},{"key":"10.1124\/jpet.109.152520_bib6","doi-asserted-by":"crossref","unstructured":"Brandt C, Bethmann K, Gastens AM, and L\u00f6scher W (2006) The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24: 202-211.","DOI":"10.1016\/j.nbd.2006.06.014"},{"key":"10.1124\/jpet.109.152520_bib7","doi-asserted-by":"crossref","unstructured":"Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, and Janigro D (2007) Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48: 505-516.","DOI":"10.1111\/j.1528-1167.2006.00960.x"},{"key":"10.1124\/jpet.109.152520_bib8","doi-asserted-by":"crossref","unstructured":"Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429.","DOI":"10.1016\/j.tips.2004.06.002"},{"key":"10.1124\/jpet.109.152520_bib9","doi-asserted-by":"crossref","unstructured":"Fujikawa DG, Daniels AH, and Kim JS (1994) The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Res 17: 207-219.","DOI":"10.1016\/0920-1211(94)90051-5"},{"key":"10.1124\/jpet.109.152520_bib10","doi-asserted-by":"crossref","unstructured":"Fujikawa DG, Shinmei SS, and Cai B (2000) Seizure-induced neuronal necrosis: implications for programmed cell death mechanisms. Epilepsia 6 (Suppl 41): S9-S13.","DOI":"10.1111\/j.1528-1157.2000.tb01549.x"},{"key":"10.1124\/jpet.109.152520_bib11","doi-asserted-by":"crossref","unstructured":"Glien M, Brandt C, Potschka H, Voigt H, Ebert U, and L\u00f6scher W (2001) Repeated low-dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy. Epilepsy Res 46: 111-119.","DOI":"10.1016\/S0920-1211(01)00272-8"},{"key":"10.1124\/jpet.109.152520_bib12","doi-asserted-by":"crossref","unstructured":"Hallinan EA, Hagen TJ, Tsymbalov S, Husa RK, Lee AC, Stapelfeld A, and Savage MA (1996) Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. J Med Chem 39: 609-613.","DOI":"10.1021\/jm950454k"},{"key":"10.1124\/jpet.109.152520_bib13","doi-asserted-by":"crossref","unstructured":"Hata AN and Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147-166.","DOI":"10.1016\/j.pharmthera.2004.06.003"},{"key":"10.1124\/jpet.109.152520_bib14","doi-asserted-by":"crossref","unstructured":"Hoffmann K, Gastens AM, Volk HA, and L\u00f6scher W (2006) Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res 69: 1-14.","DOI":"10.1016\/j.eplepsyres.2005.12.005"},{"key":"10.1124\/jpet.109.152520_bib15","doi-asserted-by":"crossref","unstructured":"Hughes JR (2008) One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol Res 30: 920-925.","DOI":"10.1179\/174313208X319116"},{"key":"10.1124\/jpet.109.152520_bib16","doi-asserted-by":"crossref","unstructured":"Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, and Iadecola C (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12: 225-229.","DOI":"10.1038\/nm1362"},{"key":"10.1124\/jpet.109.152520_bib17","doi-asserted-by":"crossref","unstructured":"Kim DK and Jang TJ (2006) Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure. Int J Exp Pathol 87: 73-78.","DOI":"10.1111\/j.0959-9673.2006.00457.x"},{"key":"10.1124\/jpet.109.152520_bib18","doi-asserted-by":"crossref","unstructured":"Kuteykin-Teplyakov K, Brandt C, Hoffmann K, and L\u00f6scher W (2009) Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia 50: 887-897.","DOI":"10.1111\/j.1528-1167.2008.01916.x"},{"key":"10.1124\/jpet.109.152520_bib19","doi-asserted-by":"crossref","unstructured":"Kwan P and Brodie MJ (2006) Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 6: 397-406.","DOI":"10.1586\/14737175.6.3.397"},{"key":"10.1124\/jpet.109.152520_bib20","doi-asserted-by":"crossref","unstructured":"Leschziner GD, Andrew R, Leach JP, Chadwick D, Coffey AJ, Balding DJ, Bentley DR, Pirmohamed M, and Johnson MR (2007) Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet Genomics 17: 217-220.","DOI":"10.1097\/01.fpc.0000230408.23146.b1"},{"key":"10.1124\/jpet.109.152520_bib21","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W and Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602.","DOI":"10.1038\/nrn1728"},{"key":"10.1124\/jpet.109.152520_bib22","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W and Sills GJ (2007) Drug resistance in epilepsy: why is a simple explanation not enough? Epilepsia 48: 2370-2372.","DOI":"10.1111\/j.1528-1167.2007.01260_2.x"},{"key":"10.1124\/jpet.109.152520_bib23","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W, Klotz U, Zimprich F, and Schmidt D (2009) The clinical impact of pharmacogenetics on treatment of epilepsy. Epilepsia 50: 1-23.","DOI":"10.1111\/j.1528-1167.2008.01716.x"},{"key":"10.1124\/jpet.109.152520_bib24","doi-asserted-by":"crossref","unstructured":"Lukasiuk K, Dabrowski M, Adach A, and Pitk\u00e4nen A (2006) Epileptogenesis-related genes revisited. Prog Brain Res 158: 223-241.","DOI":"10.1016\/S0079-6123(06)58011-2"},{"key":"10.1124\/jpet.109.152520_bib25","doi-asserted-by":"crossref","unstructured":"Luna-Tort\u00f3s C, Fedrowitz M, and L\u00f6scher W (2008) Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55: 1364-1375.","DOI":"10.1016\/j.neuropharm.2008.08.032"},{"key":"10.1124\/jpet.109.152520_bib26","doi-asserted-by":"crossref","unstructured":"Malmberg AB, Rafferty MF, and Yaksh TL (1994) Antinociceptive effect of spinally delivered prostaglandin E receptor antagonists in the formalin test on the rat. Neurosci Lett 173: 193-196.","DOI":"10.1016\/0304-3940(94)90181-3"},{"key":"10.1124\/jpet.109.152520_bib27","doi-asserted-by":"crossref","unstructured":"Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, Baumgartner C, Janigro D, Caccia S, and Vezzani A (2005) A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46: 1613-1619.","DOI":"10.1111\/j.1528-1167.2005.00265.x"},{"key":"10.1124\/jpet.109.152520_bib28","doi-asserted-by":"crossref","unstructured":"McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, and Andreasson K (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24: 257-268.","DOI":"10.1523\/JNEUROSCI.4485-03.2004"},{"key":"10.1124\/jpet.109.152520_bib29","doi-asserted-by":"crossref","unstructured":"Meldrum BS (1993) Excitotoxicity and selective neuronal loss in epilepsy. Brain Pathol 3: 405-412.","DOI":"10.1111\/j.1750-3639.1993.tb00768.x"},{"key":"10.1124\/jpet.109.152520_bib30","doi-asserted-by":"crossref","unstructured":"Miller DS, Bauer B, and Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209.","DOI":"10.1124\/pr.107.07109"},{"key":"10.1124\/jpet.109.152520_bib31","doi-asserted-by":"crossref","unstructured":"Mody I and MacDonald JF (1995) NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol Sci 16: 356-359.","DOI":"10.1016\/S0165-6147(00)89070-7"},{"key":"10.1124\/jpet.109.152520_bib32","doi-asserted-by":"crossref","unstructured":"Pekcec A, Fuest C, M\u00fchlenhoff M, Gerardy-Schahn R, and Potschka H (2008) Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. J Neurochem 105: 389-400.","DOI":"10.1111\/j.1471-4159.2007.05172.x"},{"key":"10.1124\/jpet.109.152520_bib33","doi-asserted-by":"crossref","unstructured":"Pekcec A, M\u00fchlenhoff M, Gerardy-Schahn R, and Potschka H (2007) Impact of the PSA-NCAM system on pathophysiology in a chronic rodent model of temporal lobe epilepsy. Neurobiol Dis 27: 54-66.","DOI":"10.1016\/j.nbd.2007.04.002"},{"key":"10.1124\/jpet.109.152520_bib34","doi-asserted-by":"crossref","unstructured":"Pekcec A, Unkr\u00fcer B, Stein V, Bankstahl JP, Soerensen J, Tipold A, Baumg\u00e4rtner W, and Potschka H (2009) Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res 83: 144-151.","DOI":"10.1016\/j.eplepsyres.2008.10.010"},{"key":"10.1124\/jpet.109.152520_bib35","doi-asserted-by":"crossref","unstructured":"Potschka H, Fedrowitz M, and L\u00f6scher W (2002) P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 327: 173-176.","DOI":"10.1016\/S0304-3940(02)00423-8"},{"key":"10.1124\/jpet.109.152520_bib36","doi-asserted-by":"crossref","unstructured":"Potschka H, Volk HA, and L\u00f6scher W (2004) Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 15: 1657-1661.","DOI":"10.1097\/01.wnr.0000134840.10390.a4"},{"key":"10.1124\/jpet.109.152520_bib37","doi-asserted-by":"crossref","unstructured":"Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32: 281-294.","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"10.1124\/jpet.109.152520_bib38","doi-asserted-by":"crossref","unstructured":"Rao JS, Ertley RN, Rapoport SI, Bazinet RP, and Lee HJ (2007) Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem 102: 1918-1927.","DOI":"10.1111\/j.1471-4159.2007.04648.x"},{"key":"10.1124\/jpet.109.152520_bib39","doi-asserted-by":"crossref","unstructured":"Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D\u2019Incalci M, et al. (2002) Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22: 5833-5839.","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002"},{"key":"10.1124\/jpet.109.152520_bib40","doi-asserted-by":"crossref","unstructured":"Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, and Hermann DM (2006) Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 9: 487-488.","DOI":"10.1038\/nn1676"},{"key":"10.1124\/jpet.109.152520_bib41","doi-asserted-by":"crossref","unstructured":"Suganami T, Mori K, Tanaka I, Mukoyama M, Sugawara A, Makino H, Muro S, Yahata K, Ohuchida S, Maruyama T, et al. (2003) Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 42: 1183-1190.","DOI":"10.1161\/01.HYP.0000101689.64849.97"},{"key":"10.1124\/jpet.109.152520_bib42","doi-asserted-by":"crossref","unstructured":"Takemiya T, Maehara M, Matsumura K, Yasuda S, Sugiura H, and Yamagata K (2006) Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci Res 56: 103-110.","DOI":"10.1016\/j.neures.2006.06.003"},{"key":"10.1124\/jpet.109.152520_bib43","doi-asserted-by":"crossref","unstructured":"van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, and Gorter JA (2006) Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47: 672-680.","DOI":"10.1111\/j.1528-1167.2006.00496.x"},{"key":"10.1124\/jpet.109.152520_bib44","doi-asserted-by":"crossref","unstructured":"van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, Wadman WJ, and Gorter JA (2007) Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 322: 141-147.","DOI":"10.1124\/jpet.107.121178"},{"key":"10.1124\/jpet.109.152520_bib45","doi-asserted-by":"crossref","unstructured":"Vezzani A and Granata T (2005) Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46: 1724-1743.","DOI":"10.1111\/j.1528-1167.2005.00298.x"},{"key":"10.1124\/jpet.109.152520_bib46","doi-asserted-by":"crossref","unstructured":"Volk HA and L\u00f6scher W (2005) Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 128: 1358-1368.","DOI":"10.1093\/brain\/awh437"},{"key":"10.1124\/jpet.109.152520_bib47","doi-asserted-by":"crossref","unstructured":"Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, and L\u00f6scher W (2004a) Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123: 751-759.","DOI":"10.1016\/j.neuroscience.2003.10.012"},{"key":"10.1124\/jpet.109.152520_bib48","doi-asserted-by":"crossref","unstructured":"Volk HA, Potschka H, and L\u00f6scher W (2004b) Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 58: 67-79.","DOI":"10.1016\/j.eplepsyres.2003.12.009"},{"key":"10.1124\/jpet.109.152520_bib49","doi-asserted-by":"crossref","unstructured":"Volk H, Potschka H, and L\u00f6scher W (2005) Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 53: 517-531.","DOI":"10.1369\/jhc.4A6451.2005"},{"key":"10.1124\/jpet.109.152520_bib50","doi-asserted-by":"crossref","unstructured":"Wen T, Liu YC, Yang HW, Liu HY, Liu XD, Wang GJ, and Xie L (2008) Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J Neurol Sci 270: 99-106.","DOI":"10.1016\/j.jns.2008.02.016"},{"key":"10.1124\/jpet.109.152520_bib51","doi-asserted-by":"crossref","unstructured":"West MJ, Slomianka L, and Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.","DOI":"10.1002\/ar.1092310411"},{"key":"10.1124\/jpet.109.152520_bib52","doi-asserted-by":"crossref","unstructured":"Yang H and Chen C (2008) Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 14: 1443-1451.","DOI":"10.2174\/138161208784480144"},{"key":"10.1124\/jpet.109.152520_bib53","doi-asserted-by":"crossref","unstructured":"Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsuchou H, and Pan W (2008) Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia. Cell Physiol Biochem 22: 745-756.","DOI":"10.1159\/000185558"},{"key":"10.1124\/jpet.109.152520_bib54","doi-asserted-by":"crossref","unstructured":"Zibell G, Unkr\u00fcer B, Pekcec A, Hartz AM, Bauer B, Miller DS, and Potschka H (2009) Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 56: 849-855.","DOI":"10.1016\/j.neuropharm.2009.01.009"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524385969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524385969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.152520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T01:36:23Z","timestamp":1740015383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524385969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0022356524385969"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.152520","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Prostaglandin E2 EP1 Receptors Prevents Seizure-Associated P-glycoprotein Up-Regulation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.152520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}